-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

Benzinga·08/05/2026 18:04:52
Listen to the news
Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.